Form 8-K · Current Report · Filed 2026-05-07
Danaher Corporation Shareholders Approve Incentive Plan Amendment
On May 5, 2026, Danaher Corporation's shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan, which increases the share reserve by 20 million shares and extends the plan term to May 5, 2036.
- Filer
- Danaher Corporation DHR · NYSE
- Filed
- Accession
- 0000313616-26-000127
- CIK
- 0000313616
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The annual meeting also saw the election of eleven directors and the ratification of Ernst & Young LLP as the independent auditor for the year ending December 31, 2026.
Items reported
Reported Item
Market reaction
Close before filing
$174.92
Next session
-2.1%
Since filing
+11.5%
Latest close
$194.98
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DHR reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, DHR insiders reported 17 Form 4 transactions — net selling of $45K.
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Never miss another DHR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.